Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Regulating off-label drug use--rethinking the role of the FDA.

× No keyword cloud information.

65 in total

Review 1. Off-label use of anti-cancer drugs between clinical practice and research: the Italian experience.

Authors: Rosa Lerose; Pellegrino Musto; Michele Aieta; Carla Papa; Alfredo Tartarone
Journal: Eur J Clin Pharmacol Date: 2011-12-14 Impact factor: 2.953

Review 2. [Off-label therapy: current problems from the perspective of the Pharmaceutical Commission of the German Medical Profession].

Authors: R W C Janzen; W D Ludwig
Journal: Z Rheumatol Date: 2012-02 Impact factor: 1.372

3. Off-label use of atypical antipsychotics: cause for concern?

Authors: Andrew McKean; Erik Monasterio
Journal: CNS Drugs Date: 2012-05-01 Impact factor: 5.749

4. Off-label prescribing in older people: the need for increased awareness and caution.

Authors: Anne Stephenson; Geoffrey M Anderson; Paula Rochon
Journal: Drugs Aging Date: 2012-06-01 Impact factor: 3.923

Review 5. Off-label prescribing in older patients.

Authors: Stephen H D Jackson; Paul A F Jansen; Arduino A Mangoni
Journal: Drugs Aging Date: 2012-06-01 Impact factor: 3.923

6. Off-licence prescribing and regulation in psychiatry: current challenges require a new model of governance.

Authors: Philip Sugarman; Amy Mitchell; Catherine Frogley; Geoffrey L Dickens; Marco Picchioni
Journal: Ther Adv Psychopharmacol Date: 2013-08

7. The use of off-label medications in substance abuse treatment programs.

Authors: Maria Paino; Lydia Aletraris; Paul M Roman
Journal: Subst Abus Date: 2019-07-30 Impact factor: 3.716

8. Risk management policy and black-box warnings: a qualitative analysis of US FDA proceedings.

Authors: Daniel M Cook; Rama K Gurugubelli; Lisa A Bero
Journal: Drug Saf Date: 2009 Impact factor: 5.606

9. Colon cancer patient information seeking and the adoption of targeted therapy for on-label and off-label indications.

Authors: Stacy W Gray; Katrina Armstrong; Angela Demichele; J Sanford Schwartz; Robert C Hornik
Journal: Cancer Date: 2009-04-01 Impact factor: 6.860

Review 10. Intravitreal Bevacizumab and Cardiovascular Risk in Patients with Age-Related Macular Degeneration: Systematic Review and Meta-Analysis of Randomized Controlled Trials and Observational Studies.

Authors: Ivana Mikačić; Damir Bosnar
Journal: Drug Saf Date: 2016-06 Impact factor: 5.606